Immunex Files Supplemental NDA for NOVANTRONE

Company seeks priority review of NOVATRONE in secondary progressive Multiple Sclerosis

SEATTLE - Immunex Corporation (NASDAQ:IMNX) announced today that it has filed a supplemental NDA with the U.S. Food and Drug Administration (FDA) for expanded labeling for NOVANTRONE® (mitoxantrone for injection concentrate) for the treatment of patients with secondary progressive Multiple Sclerosis (MS).

"There are 120,000 patients with secondary progressive MS for whom there are still no approved treatment options," said Peggy V. Phillips, senior vice president, pharmaceutical development for Immunex. "Patients with this form of the disease experience a steady worsening of their neurological function which can result in loss of control over movement of limbs and impaired vision and speech. We are pleased to be filing this and we have asked the FDA for priority review."

The results of the pivotal NOVANTRONE Phase III data submitted to the FDA today showed that NOVANTRONE had a statistically significant impact on relapse rate and disability progression in patients with secondary progressive MS. These clinical data were corroborated by positive magnetic resonance imaging (MRI) data.

This multicenter, placebo-controlled, randomized, observer-blind study of 194 patients compared two doses of NOVANTRONE -- 12 mg/m2 and 5 mg/m2 - with placebo. Each treatment was administered by short, IV infusion once every three months for two years. These results were reported at the September 1998 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

Additional third-year follow-up data were presented in April of this year at the Annual Meeting of the American Academy of Neurology (AAN). These results showed that one year after treatment was stopped, patients who had been treated with NOVANTRONE experienced a sustained reduction in their number of attacks, and delay in their disab

Contact: Lisa Crisera
Immunex Corporation

Page: 1 2 3

Related medicine news :

1. Immunex Advances CD40 Ligand To Phase II Clinical Trial In People With Metastatic Kidney Cancer
2. Immunexs TRAIL Molecule Shows Potential As Anti-Tumor Agent
3. Mad hatters, seafood jubilees, & Pfiesteria Files
4. NOVANTRONE application for multiple sclerosis granted priority review by FDA

Post Your Comments:

(Date:11/14/2018)... ... November 14, 2018 , ... ... the All-In-One Video Ecommerce Solution, to power its "Ask an Expert" online mentor ... in live 30 and 60-minute one-to-one virtual sessions that are focused on starting ...
(Date:11/14/2018)... ... November 14, 2018 , ... For what is a first time at ... for Eating Disorders, will present an overview of the EFFT model with a focus ... at the 2019 event. , Next year’s 33rd iaedp™ Symposium is slated for ...
(Date:11/14/2018)... Ind. (PRWEB) , ... November 14, 2018 , ... ... 25mm lengths to its FortiCore® rotatable Posterior Lumbar Interbody Fusion (PLIF) devices. , ... driven growth with the expansion of their FortiCore PLIF product line with the addition ...
(Date:11/13/2018)... ... 13, 2018 , ... A survey by the publishers of ADC Review ... antibody therapies reached U.S. $ 4 billion. Approximately forty-five percent of this market included ... therapies (including ADCs) is expected to grow significantly, to U.S. $ 17 billion by ...
(Date:11/13/2018)... CLAREMONT, Calif. (PRWEB) , ... November 13, 2018 ... ... Surgeon General called for increased awareness and use of naloxone, an opioid overdose ... trained pharmacists to provide naloxone to individuals without a prescription. , ...
Breaking Medicine News(10 mins):
(Date:11/15/2018)... ... November 15, 2018 , ... ... healthcare organizations, today announced a strategic partnership with Formativ Health, a technology-enabled, ... Connector will perform platform integrations that connect Formativ Health’s clients’ Healthcare IT ...
(Date:11/15/2018)... ... November 15, 2018 , ... Mobile exoskeleton ... estimated to continue its dominance during the study period. The segment growth is ... to the wearer while augmenting strength to lift heavy load. Stationary products are ...
(Date:11/15/2018)... ... November 15, 2018 , ... This exclusive ranking ... moving our economy forward. The award, known as the Omni500, represents the most ... of sustainable growth among the communities they serve.2018 marks OMNIKAL’S 18th annual listing ...
Breaking Medicine Technology:
Cached News: